KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

NCT05421429 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia

Interventions

BIOLOGICAL: KN057 doseⅠ
BIOLOGICAL: KN057 dose Ⅱ
BIOLOGICAL: KN057 dose Ⅲ

Sponsor

Suzhou Alphamab Co., Ltd.